Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000296181 encodes a novel, uncharacterized natural antisense transcript (NAT) oriented antisense to the zinc finger homeobox-3 (ZFHX3) gene. NATs are long non-coding RNAs (lncRNAs) transcribed from the opposite DNA strand of protein-coding or non-coding genes, often overlapping exons or regulatory regions of their partner gene[1]. For this specific transcript, there is no direct functional characterization or evidence supporting a role as a therapeutic target, nor association with drug interactions or specific disease. However, antisense lncRNAs are generally known to regulate their sense gene’s expression through mechanisms such as mRNA stabilization, interference with splicing, or chromatin modification, sometimes with tissue- and development-specific expression patterns[1]. ZFHX3, the sense gene counterpart, is a transcription factor crucial for nervous system development and circadian rhythm maintenance; by analogy, its antisense transcript may play a regulatory role in these pathways, but this remains speculative due to absence of supporting experimental data for ENSG00000296181.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to zinc finger homeobox-3 (ENSG00000296181).